Market Place
Sourcing Support
Bioverativ`s Biologic Enjaymo (sutimlimab) Receives Approval in the U.S.
09 Feb 2024 //
FDA
Bioverativ`s Biologic Enjaymo ( Sutimlimab) Receives Approval in the U.S.
25 Jan 2023 //
FDA
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
Therapeutic-first for cold agglutinin disease haemolytic anaemia
21 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
EC approves Enjaymo for treatment of hemolytic anemia
17 Nov 2022 //
PRESS RELEASE
Genzyme`s Enjaymo (sutimlimab) Receives Approval in the Europe
17 Nov 2022 //
EMA
EMA committee recommends Sanofi’s Enjaymo`s approval for haemolytic anaemia
19 Sep 2022 //
PHARMABIZ
CHMP recommends approval of Enjaymo™ (sutimlimab), first and only approved
16 Sep 2022 //
PRESS RELEASE
Sanofi`s treatment for rare anemia hits goal in 2nd phase 3
12 Jun 2021 //
FIERCE BIOTECH
Sanofi grapples with rejection of potential first-class orphan drug, faults MFG
16 Nov 2020 //
ENDPTS
FDA issues Complete Response Letter for sutimlimab, an investigational
14 Nov 2020 //
PHARMIWEB
Sanofi gets priority FDA review for sutimlimab product
14 May 2020 //
REUTERS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.